BIOTRONIKS-Safety and Clinical Performance of the First Drug-Eluting Generation Absorbable Metal Stent In Patients with de Novo Lesions in Native Coronary Arteries (BIOSOLVE-I study) - BIOSOLVE-I Study

Biotronik AG0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1. Patient is between >/= 18 year and 2. Written patient informed consent available prior to PCI
•3. Patients with stable or unstable angina pectoris or documented silent ischemia
•4. Patient eligible for PCI
•5. Patient acceptable candidate for coronary artery bypass surgery
•6. Patients with a maximum of two lesions in two separate coronary arteries which have to be de novo lesions.
•7. Target reference vessel diameter by visual estimation, assisted by QCA / IVUS: 3.0 - 3.5 mm
•8. Target lesion length by visual estimation, assisted by QCA / IVUS: 9. Target lesion stenosis by visual estimation, assisted by QCA / IVUS: >/= 50% - < 100%

•1. Left ventricular ejection fraction of < 30%
•2. Patients with three-vessel where all three vessels require treatment
•3. Myocardial infarction (STEMI/NSTEMI) within 4 weeks of the intended treatment. Determination of CKMB and/or troponin T or I is required.
•Laboratory assessments to be done within 24 hours prior to intervention.
•Patients with CKMB and/or troponin T or I > 3 fold the upper limit of normal must not be included in the trial.
•4. Patients with risk of either acetylsalicylic acid, clopidogrel or Prasugrel cessation
•5. Impaired renal function (serum creatinine > 2.0mg/dl or 177 umol/l, determined within 72 hours prior to intervention)
•6. Additional coronary lesions (restenotic or de novo) in the same vessel which requires treatment
•7. Lesions located within arterial or venous graft
•8. Ostial lesions

发起方